Neurocrine Biosciences (NBIX) News Today $94.89 +4.02 (+4.42%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period RBC Capital Upgrades Neurocrine Biosciences (NBIX)April 15 at 1:43 AM | msn.comNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial ResultsApril 14 at 5:39 PM | gurufocus.comNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial ...April 14 at 4:40 PM | gurufocus.comNeurocrine upgraded to Outperform from Sector Perform at RBC CapitalApril 14 at 3:42 PM | markets.businessinsider.comNeurocrine upgraded to Outperform at RBC Capital following pullbackApril 14 at 3:42 PM | markets.businessinsider.comNeurocrine Biosciences Inc (NBIX) Shares Up 4.15% on Apr 14April 14 at 1:59 PM | gurufocus.comPhiladelphia Trust Co. Acquires 29,685 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Philadelphia Trust Co. grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 441.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,410 shares of the company's stock after purchasing an additional 29,685 shApril 14 at 7:03 AM | marketbeat.comFortis Capital Advisors LLC Takes $1.13 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fortis Capital Advisors LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,852 shares of the company's stoApril 14 at 6:42 AM | marketbeat.comCapital Fund Management S.A. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Capital Fund Management S.A. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 6.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 104,524 shares of the company's stock after selling 7,048 shares during the periodApril 14 at 5:50 AM | marketbeat.comFederated Hermes Inc. Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Federated Hermes Inc. trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 60.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,843 shares of theApril 14 at 4:31 AM | marketbeat.comAPG Asset Management N.V. Takes $7.93 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)APG Asset Management N.V. purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 60,189 shares of the company's stock, valued at aApril 13 at 5:56 AM | marketbeat.comWells Fargo & Company MN Decreases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wells Fargo & Company MN lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 246,579 shares of the company's stock afApril 13 at 4:48 AM | marketbeat.comMartingale Asset Management L P Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Martingale Asset Management L P lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 22,855 shares of the company's stock after selling 3,456 shares duApril 12 at 6:49 AM | marketbeat.comRussell Investments Group Ltd. Sells 84,560 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Russell Investments Group Ltd. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,217 shares of the compaApril 12 at 5:22 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stake Lifted by Aviva PLCAviva PLC increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 157.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,918 shares ofApril 11, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Reaches New 52-Week Low - Here's What HappenedNeurocrine Biosciences (NASDAQ:NBIX) Hits New 1-Year Low - Should You Sell?April 11, 2025 | marketbeat.comExodusPoint Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)ExodusPoint Capital Management LP bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 15,844 shares of the company's stock, valued at approximately $2,163,000. Other hedge fApril 11, 2025 | marketbeat.comNeurocrine price target lowered to $155 from $163 at GuggenheimApril 10, 2025 | markets.businessinsider.comRenaissance Group LLC Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Renaissance Group LLC raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 6.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 217,572 shares of the company's stock after buying an additApril 10, 2025 | marketbeat.comRenaissance Technologies LLC Reduces Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Renaissance Technologies LLC lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,489,397 shares of the company's stock afteApril 10, 2025 | marketbeat.comResona Asset Management Co. Ltd. Invests $6.81 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Resona Asset Management Co. Ltd. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 49,838 shareApril 10, 2025 | marketbeat.com2Xideas AG Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)2Xideas AG bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 109,018 shares of the company's stock, valued at approximately $14,881,000April 8, 2025 | marketbeat.com48,000 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Atika Capital Management LLCAtika Capital Management LLC acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 48,000 shares of the company's stock, valued at approximately $6,552,000. A numberApril 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Sells 12,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Massachusetts Financial Services Co. MA lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 150,331 shares of the cApril 8, 2025 | marketbeat.comNBIX Quantitative Stock Analysis - Peter LynchApril 7, 2025 | nasdaq.comRhenman & Partners Asset Management AB Purchases 28,567 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Rhenman & Partners Asset Management AB lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 39.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 100,317 shares of the company's stock after acquiring an additiApril 7, 2025 | marketbeat.comGeode Capital Management LLC Acquires 15,830 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Geode Capital Management LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 0.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,875,062 shares of the company's stoApril 7, 2025 | marketbeat.comNeurocrine Biosciences names new Chief Medical OfficerApril 6, 2025 | uk.investing.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $137.00 by Analysts at UBS GroupUBS Group dropped their price objective on Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating for the company in a research note on Friday.April 6, 2025 | marketbeat.comTrexquant Investment LP Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Trexquant Investment LP trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 43.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,186 shares of the company's stock after selling 43,163 shares duApril 6, 2025 | marketbeat.comNorges Bank Invests $44.40 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Norges Bank bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 325,295 shares of the company's stock, valued at approximately $44,403,000. Norges Bank ownApril 6, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given New $137.00 Price Target at UBS GroupApril 6, 2025 | americanbankingnews.comCinctive Capital Management LP Purchases Shares of 16,366 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Cinctive Capital Management LP purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,366 shares of the company's stApril 5, 2025 | marketbeat.comFranklin Resources Inc. Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Franklin Resources Inc. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 608,935 shares of the company's stock after selling 55,401 sharesApril 5, 2025 | marketbeat.comAlliancebernstein L.P. Sells 59,298 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Alliancebernstein L.P. trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 577,616 shares of the company's stApril 5, 2025 | marketbeat.comNeurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4, 2025 | finanznachrichten.deNeurocrine price target lowered to $137 from $154 at UBSApril 4, 2025 | markets.businessinsider.comNeurocrine names Dr. Sanjay Keswani as Chief Medical OfficerApril 4, 2025 | markets.businessinsider.comNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4, 2025 | gurufocus.comNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4, 2025 | gurufocus.comNeurocrine Biosciences Appoints Dr. Keswani as CMOApril 4, 2025 | tipranks.comNeurocrine Biosciences names Sanjay Keswani as chief medical officerApril 4, 2025 | seekingalpha.comNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4, 2025 | prnewswire.comHeadlands Technologies LLC Sells 13,566 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Headlands Technologies LLC lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 69.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,837 shares of the company's stock after selling 13,566 sharApril 4, 2025 | marketbeat.comWellington Management Group LLP Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wellington Management Group LLP grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 102.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,457,425 shares of thApril 4, 2025 | marketbeat.comSchroder Investment Management Group Sells 84,539 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Schroder Investment Management Group decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 126,735 shares of the company's stockApril 4, 2025 | marketbeat.comAllstate Corp Purchases Shares of 2,909 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Allstate Corp acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,909 shares of the company's stock, valued at approximateApril 4, 2025 | marketbeat.comWells Fargo Sticks to Their Buy Rating for Neurocrine (NBIX)April 3, 2025 | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by California Public Employees Retirement SystemCalifornia Public Employees Retirement System cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 453,091 shares of the company's stock after selling 9April 3, 2025 | marketbeat.comAmerican Century Companies Inc. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)American Century Companies Inc. lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 49.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,523 shares of the company's stock after selling 88,727 shApril 3, 2025 | marketbeat.com Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.220.80▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼2515▲NBIX Articles Average Week Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Exelixis News Today Exact Sciences News Today Halozyme Therapeutics News Today Repligen News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
